Login / Signup

Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease.

Carles GaigYaroslau ComptaAnna HeidbrederMaria J MartiMaarten J TitulaerYvette CrijnenBirgit HöglJan LewerenzMaria Elena ErroJuan Carlos Garcia-MoncoPasquale NigroNicola TambascoMaja Patalong-OgiewaMarcus ErdlerStefan MacherEvelyn Berger-SieczkowskiRomana HöftbergerChristian GeisMarkus HuttererAngela Milán-TomásAntonio Martin-BastidaLydia Lopez ManzanaresSonia QuintasGünter U HöglingerNora MöhnFlorian SchoeberlFranziska S ThalerGian Maria AsioliFederica ProviniGiuseppe PlazziKoldo BerganzoMorten BlaabjergNorbert BrüggemannTarsis FariasChen Fei NgCaroline GiordanaAlejandro Herrero-San MartínLucio HuebraKatya KotschetHerburg LiendlTeresa MontojoCarlos MorataJesus Perez PerezInmaculada PuertasThomas Seifert-HeldCaspar B SeitzMateus Mistieri SimabukuroNieves TellezJavier Villacieros-ÁlvarezBarbara WillekensLidia SabaterAlex IranzoJoan Santamaria CanoJosep DalmauFrancesc Graus
Published in: Neurology (2021)
Movement disorders are a frequent and leading cause of initial neurological consultation in patients with anti-IgLON5 disease. Although multiple types of abnormal movements can occur, the most prevalent are disorders of gait, generalized chorea, and dystonia and other dyskinesias that frequently affect craniofacial muscles. Overall, anti-IgLON5 disease should be considered in patients with multiple movement disorders, particularly if they occur in association with sleep alterations, bulbar dysfunction, or cognitive impairment.
Keyphrases
  • cognitive impairment
  • palliative care
  • early onset
  • oxidative stress
  • physical activity
  • subarachnoid hemorrhage